Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials

Affiliations

¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON L8S 4K1, Canada. Electronic address: gerstein@mcmaster.ca.

Comment

Hertzel C Gerstein. Lancet Diabetes Endocrinol. 2020 Jul.

. 2020 Jul;8(7):557-558.

doi: 10.1016/S2213-8587(20)30187-X.

¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON L8S 4K1, Canada. Electronic address: gerstein@mcmaster.ca.

No abstract available

Comment on

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476